NEWS AGAIN and should soon reach new highs

NOW Sphry hitting 18..Up and AWAY Again

now hitting 16 up up and away

KABOOM SPHRY over 14 now

SPHRY 12.62 and rising

STARPHAMA CASH FLOW EXCELLENT

https://starpharma.com/news/528

Peachman still making money as SPHRY keeps rising close 13

Another good day at STARPHAMA 11.65

SPHRY up again over 10.50

sphry still going up

MORE SPHRY NEWS

https://starpharma.com/news/502

More SPHRY news.

https://starpharma.com/news/492

Not sure if PRED,PASO WUHN or SPHRY will help me retire first..maybe they all will

SPHRY climbing upward

Loading up shares of SPHRY under 8 in my opinion is smart for the long haul

NEW Starpharma update

https://starpharma.com/news/462

new Starphama update OcT 1

https://starpharma.com/news/436

New Starphama update


First Asian Regulatory Approvals Received for VivaGel


https://starpharma.com/news/428

August update on Starphama

https://starpharma.com/news/427

July update on SPHRY

https://starpharma.com/news/424

More Great news SPHRY

https://starpharma.com/news/425

VivaGel® BV has been launched in Europe by Mundipharma, under the brand name Betadine BVTM
Betadine BVTM will be available Over-The-Counter, without prescription
Mundipharma is rolling out Betadine BVTM throughout Europe during the year
European launch triggers a milestone payment of US$0.5M (A$0.72M)
Starpharma is eligible to earn total milestones up to US$24.7M, plus revenue share, for all territories under Mundipharma’s licence
Regulatory activities are underway for multiple countries across other Mundipharma regions
Melbourne, Australia; 27 June 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VivaGel® BV has been launched in Europe under the brand name Betadine BVTM. The product has been launched in several countries in Europe, including Germany, with further roll-out in additional European countries during the year.

Betadine BVTM will be available over-the-counter (OTC), without the need to see a doctor or obtain a prescription. Europe is the second region to launch VivaGel® BV and represents a large commercial opportunity with access to more than 260 million women.

VivaGel® BV (Betadine BVTM) is a novel, non-antibiotic therapy for treatment and prevention of bacterial vaginosis (BV). BV is the most common vaginal condition worldwide and twice as common as thrush. VivaGel® BV (Betadine BVTM) is an Australian innovation –invented, fully developed and taken through to commercialisation by Starpharma.

BV is a troublesome and often recurrent condition that causes unpleasant vaginal odour and discharge symptoms that have significant social impacts for women. BV has also been associated with a range of other serious reproductive health-related medical problems.

Betadine BVTM is being marketed by Mundipharma, a leading global pharmaceutical company which owns the successful international brand BETADINE®. Mundipharma is one of the largest privately-owned pharmaceutical companies in the world employing over 8,600 people.

The launch of Betadine BVTM in Europe triggers a milestone payment of US$0.5M (A$0.72M) to Starpharma. Starpharma is eligible to earn total milestones up to US$24.7M, plus revenue share, for all territories under Mundipharma’s licence.

Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to achieve another territory launch of VivaGel® BV this year, and our first with Mundipharma. Europe represents a very important market for VivaGel® BV and we’re delighted that our breakthrough product will be available to millions of European women who suffer from BV. Mundipharma have a excellent track record in the OTC space and a leading position in feminine care with their successful international brand BETADINE®. We look forward to working with Mundipharma on further registrations and launches across the globe”.

Raman Singh, Mundipharma CEO, commented: “We are delighted to launch Betadine BVTM in Europe. This product represents a true innovation in the management of bacterial vaginosis (BV). It sits well under the BETADINE® brand, which has emerged as a powerful brand platform for consumer healthcare products, trusted by women globally.”

Starpharma’s and Mundipharma’s marketing and regulatory teams continue to work actively together on further launches of VivaGel® BV in Europe and also in other regions, such as Asia. Regulatory activities are underway for multiple countries across Mundipharma’s regions.

Download ASX Announcement: VivaGel® BV launched in Europe (PDF, 70kb)

SPHRY presenting in Melbourne

https://starpharma.com/news/423

https://www.starpharma.com/assets/uploads/2019-06/190620StarpharmaPresentationMacquarieWeb.pdf

More Great news today at SPHRY

US patent granted for DEP Bcl2/xL inhibitor conjugates


https://starpharma.com/news/422

Everyday new news on SPHRY

Wonder when my friends on IHUB will join this company.

I'm predicting double this year from here

Okamoto launches VivaGel® condom in Japan

https://starpharma.com/news/421

More news on SPHRY today


https://starpharma.com/assets/asxannouncements/190603%20Starpharma%20signs%20second%20oncology%20agreement%20with%20AZ%20final.pdf

https://starpharma.com/news/420

More news on SPHRY May 29th

https://starpharma.com/news/419

https://www.starpharma.com/assets/uploads/2019-05/190529StarpharmaPresentationUBS_conference-web.pdf

Not going to see pps under 9 much longer at SPHY

https://starpharma.com/news-room

Starphama presents at Macquarie Australia Conference

https://starpharma.com/news/415

Another STARPHARMA update should cause increase in pps today and moving forward.

https://starpharma.com/news/407

Starpharma update

https://starpharma.com/news/406

https://starpharma.com/news

https://starpharma.com/assets/asxannouncements/190318%20Shareholder%20Update%20March%202019.pdf

Educate yourself buy Starpharma and hold

Why not spend some time in learning why Starpharma and you are going to be successful?

Please do the following.

1. Go to YouTube

2. In the Search Box enter: Nanotechnology+ Dendrimers

3. From the list of videos, select: 'Dendrimer Based Nanomedicine: Engineering Nanoparticles'

Note: Starpharma meets with the FDA this week, the second week in April 2019

In My opinion great opportunity between under 8

PPS keeps rising this month in anticipation of MID April meeting for SPHRY.

Time to be adding now under 7 and 8

›› FDA meeting to discuss VivaGel® BV
approval in the US
In preparation for the upcoming meeting with the FDA, Starpharma
has completed and submitted a comprehensive package of
information, including further analyses of existing clinical data for
VivaGel® BV. A meeting with the FDA is expected to occur in the
second week of April 2019, subject to final confirmation of availability
of all parties. The meeting will be attended by senior representatives
of Starpharma as well as internationally recognised KOLs in the area
of BV, and the Company’s expert FDA regulatory consultants.
Since receiving the FDA’s request for confirmatory clinical data,
Starpharma has undertaken a comprehensive program with a view
to expediting approval, which has included extensive regulatory
advice from FDA experts and specialist US legal counsel. The
information submitted for the meeting, which includes additional
statistical analyses of existing data, was prepared in consultation
with, and following input from Starpharma’s team of expert FDA
consultants, including former senior FDA personnel, KOLs and
statisticians. These analyses provide further support for the approval
of VivaGel® BV.
The meeting is expected to clarify what confirmatory data will be
required for approval and whether the requirement can be satisfied
by additional analyses of existing clinical data, or whether this will
require the generation of new confirmatory clinical data. Starpharma
will be in a position to provide additional information following the
FDA meeting, once the outcomes of the discussion at the meeting
have been confirmed in writing.
Requests for additional data from the FDA are not unusual among
New Drug Applications. In 2016, almost 40% of NDAs submitted
were not approved in the first instance and additional data were
requested. A longer-term review between 2001 and 2015 showed
that 44% of NDAs were not approved upon first round review.
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”,
“aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such
forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any
existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that
they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical
data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and
additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary
materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of
new information, future events or developments or otherwise.
Feedback on VivaGel® BV from US clinicians and patients has been
extremely positive. We are looking forward to a productive and
informative meeting with the FDA. Starpharma is committed to
working with the FDA to secure approval with minimal delay to
make VivaGel® BV available to US patients as soon as possible.
Dr Jackie Fairley, CEO of Starpharma

New meeting in Mid April for Starphama with FDA could be awesome.

New news on STARPHAMA SPHRY https://starpharma.com/news/395

I have been posting and adding shares since OCT 2015.
This might be the best kept secret on IHUB

On the phone now with a stock broker and paid promoter for IFUS that says IFUS will bust 400 dollars per share easy guys!!!!!! It is a paid IFUS promo but I am down with it and on payroll myself these days. I hope that all IFUS shareholders are doing well and I would like to thank the countless IFUS shareholders that paid me a visit here recently when I was released from the hospital. Funny that the doctors gave up on me living but the IFUS shareholders DID NOT. I would like to thank all of the IFUS shareholders for their prayers and thoughts directed me to me when I was in the hospital. I am now back in IFUS action and paid buy the IFUS "inner circle" to promote and create awareness IFUS like there is no tomorrow. We want IFUS to have 3 billion share volume days to cover an IFUS stock promotion that cost 99 billon shares with some very trusted penny stock awareness/promoter guys. We can buy this promotion with IFUS common stock and run CRAZY volume on this ticker. It is all part of the plan that the serous IFUS shareholders have for the company. Do not listen to the IFUS noise but instead take the more humble path of knowing that IFUS will be the largest stock ever traded on the NYSE exchange. THANK YOU!!!!!!!!!!!!

sorry I bought some shares but I wish I HAD bought more between 5 and 10

I wish I did not buy more from 5 -10

i wish I didn't sell half to buy other positions.

Nice to see that we were correct 2 years ago about SPHRY

Starpharma will be at 15 by Christmas. I started accumulating at 5 two years ago in October

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=117768553

Starpharma just getting started

wow two years already
It's only going to go higher...


PEACHMAN Member Level Friday, 10/16/15 10:47:59 AM
Re: Michael Scofield post# 102
Post #
103
of 113 Go
A friend reviewed the different phases on research and patents that could make SPHRY pps much higher over the next few years.

Great news today pps keeps going higher

I love it when it keep going higher

SPHRY GOING HIGHER

http://www.thestreet.com/story/13498233/1/adama-licenses-starpharmas-priostar-dendrimer-technology-for-the-development-and-commercialization-of-a-novel-24-d-product-for-the-us-market.html


MELBOURNE, Australia and TEL-AVIV, Israel, March 17, 2016 /PRNewswire/ --
Starpharma (ASX:SPL; OTCQX: SPHRY) and Adama today announced the licensing by Adama of Starpharma's Priostar ® dendrimer technology for the development and commercialization of an enhanced, proprietary 2,4-D herbicide for the US market. 2,4-D is one of the top three herbicides sold world-wide, with global sales in 2014 estimated by Phillips McDougall to be around US$680 million. The US market in 2014 was worth approximately US$115 million, and has been projected by the US Department of Agriculture to grow by more than 70% by 2020.
(Logo: http://photos.prnewswire.com/prnh/20140402/679073 )
Adama has already commenced development of a novel and unique 2,4-D product containing the Priostar ® dendrimer technology, which is expected to provide better flexibility and weed control benefits to the grower, as well as improved safety. This will allow for on-target application, thus benefiting the environment by reducing the amounts of product required.
Under the license, Starpharma will receive royalties on sales of the proprietary Adama Priostar ®-improved 2,4-D products. In addition to the US, the agreement also includes a mechanism to expand the license into additional territories.
Sami Shabtai, Head of Innovative Development at Adama, commented, "As a farmer-centric company, Adama constantly strives to bring new and innovative solutions to farmers that will simplify their lives. The innovative nature and superior performance of the Priostar ® formulations fit well with our strategy to deliver simple and efficient solutions to farmers to help them grow. This is yet another step in the evolution and differentiation of our offering, as we continue to introduce unique mixtures and formulations to the market."
Dr. Jackie Fairley, CEO of Starpharma, said, "We enjoy a positive relationship with Adama, and their extensive trials of Priostar ®-improved 2,4-D formulations have led to this license agreement. With Adama's strong, proven record of innovative product development, we are very pleased to have them as commercial partners for Priostar ®-improved 2,4-D products. In addition, we continue to explore other Priostar ® product opportunities with Adama."
About Starpharma ' s Priostar® dendrimer technology:
Starpharma's Priostar® dendrimer technology offers formulation and efficacy benefits in crop protection applications including:
Improved efficacy
More concentrated formulations to reduce transport costs;
Reduction in solvent requirements; and
Increased adhesion, to reduce losses due to rain run-off, and the need for multiple applications.
About Adama
Adama is one of the world's leading crop protection companies. We strive to Create Simplicity in Agriculture - offering farmers effective and efficient products and services that simplify their lives and help them grow. With one of the most comprehensive and diversified portfolios of differentiated, high-quality products, Adama's 4,900 people reach farmers in over 100 countries across the globe, providing them with solutions to control weeds, insects and disease and improve their yields. For more information, visit us at http://www.adama.com and follow us on Twitter at @AdamaAgri.
About Starpharma Holdings Limited
Starpharma Holdings Limited, an Australian ASX 300 company, is a world leader in the development of novel products based on dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure, for pharmaceutical, life science and other applications. Starpharma has three core development programs: VivaGel ® portfolio, DEP™ drug delivery, and agrochemicals with a number of products being developed internally and externally via commercial partnerships. Partners include AstraZeneca, Ansell, and Okamoto, as well as other named and undisclosed partnerships with leading global companies in pharmaceuticals and agrochemicals. For more information please visit: http://www.starpharma.com
Contact at Adama:Nina ZoukelmanPublic Relations ManagerEmail: nina.zoukelman@adama.com Contact at Starpharma: Buchan Consulting Rebecca WilsonMob: +61-417-382-391 rwilson@buchanwe.com.auGabriella Hold+61-3-9866-4722 ghold@buchanwe.com.au Starpharma:Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary+61-3-8532-2704 investor.relations@starpharma.com http://www.starpharma.com
SOURCE Starpharma and ADAMA

Nice gain today for SPHRY

http://www.4-traders.com/STARPHARMA-HOLDINGS-LIMIT-8864716/news/Starpharma--Appendix-4C-Quarterly-Cashflow-Report-21291475/


Melbourne, Australia; 30 October 2015: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 September 2015.



The cash balance as at 30 September 2015 was $26.1 million, a net cash burn of $4.7 million from the 30 June cash balance of $30.8 million. Of note, Starpharma received in October the first payment of US$2 million from AstraZeneca following the signing of a licence. As this was received following the end of the quarter, the receipt is not reflected in the reported 30 September cash balance. The receipt of the $3.4 million R&D tax incentive is also anticipated in the December quarter.



A highlight of the September quarter was the signing of the multi-product DEP® licence with AstraZeneca for the development and commercialisation by AstraZeneca of DEP® based products directed at a defined family of targets. Under the agreement AstraZeneca will fund all development and commercialisation costs for the DEP® based products.

Starpharma is eligible to receive US$126 million in milestones for the initial compound, as well as royalties on product net sales. The AstraZeneca agreement provides for additional milestones and royalties to be payable on subsequent DEP® based products to be developed and commercialised under the license.

SPHRY has very little volume and needs awareness and financial support.

This is a longer term play .....